Aurora Schiavon

Ms. Aurora Schiavon

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ASAurora Schiavon
Aurora Schiavon
LSLaura Saba
Laura Saba
CECarlotta Evaristo
Carlotta Evaristo
Jessica PetitiJessica Petiti
Jessica Petiti
Ymera PignochinoYmera Pignochino
Ymera Pignochino
MIMarco Lo Iacono
Marco Lo Iacono
Adrenocortical Carcinoma is a rare and aggressive endocrine malignancy, that arises from cells of one of the three cortical layers of the adrenal gland. Radical surgery is the only curative treatment, even if recurrence rates are high. Therapeutic options are limited, with mitotane as the cornerstone of medical therapy. Despite 50 years of clinical use, the mechanism of action of mitotane has not yet been fully established, possibly due to the drug's susceptibility to interaction with confounding factors that reduce its biological activity. In the present study, we evaluated by RNAseq the effect of mitotane on gene expression in the H295R cell line, in an environment free of known confounding factors. Our approach allowed us to identify transcriptional deregulation of the ATF4/ATF3 axis, often involved in ER stress. These results were also validated by ddPCR in independent experiments. Mitotane-mediated ATF4 overexpression was also confirmed at the protein level. We observed how an incremental concentration of mitotane could deregulate main biological pathways. Further, we confirmed, both at RNAseq and ddPCR level, the mitotane-mediated downmodulation of genes such as STAR, CYP11A1, CYP21A2, and HSD3B2, highlighting its effect on steroid hormones biosynthesis. Through our approach, we identified biological pathways altered by mitotane in early response stages and with low drug concentrations. Some of these pathways could potentially be investigated in the future as functional biomarkers to monitor adrenocortical carcinoma treatment or as new pharmacological targets for this rare disease.

Verified
Journal Article
Open access
PDF file
Jessica PetitiJessica Petiti
Jessica Petiti
Ymera PignochinoYmera Pignochino
Ymera Pignochino
ASAurora Schiavon
Aurora Schiavon
EGEmilia Giugliano
Emilia Giugliano
EBEnrico Berrino
Enrico Berrino
MIMarco Lo Iacono
Marco Lo Iacono
Acute myeloid leukemia (AML) is a complex hematologic malignancy with high morbidity and mortality. Nucleophosmin 1 (NPM1) mutations occur in approximately 30% of AML cases, and NPM1-mutated AML is classified as a distinct entity. NPM1-mutated AML patients without additional genetic abnormalities have a favorable prognosis. Despite this, 30–50% of them experience relapse. This study aimed to investigate the potential of total RNAseq in improving the characterization of NPM1-mutated AML patients. We explored genetic variations independently of myeloid stratification, revealing a complex molecular scenario. We showed that total RNAseq enables the uncovering of different genetic alterations and clonal subtypes, allowing for a comprehensive evaluation of the real expression of exome transcripts in leukemic clones and the identification of aberrant fusion transcripts. This characterization may enhance understanding and guide improved treatment strategies for NPM1mut AML patients, contributing to better outcomes. Our findings underscore the complexity of NPM1-mutated AML, supporting the incorporation of advanced technologies for precise risk stratification and personalized therapeutic strategies. The study provides a foundation for future investigations into the clinical implications of identified genetic variations and highlights the importance of evolving diagnostic approaches in leukemia management.

25 February 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ASAurora Schiavon
Aurora Schiavon
CECarlotta Evaristo
Carlotta Evaristo
LSLaura Saba
Laura Saba
Jessica PetitiJessica Petiti
Jessica Petiti
Ymera PignochinoYmera Pignochino
Ymera Pignochino
MIMarco Lo Iacono
Marco Lo Iacono
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options. Mitotane, the only approved drug, has modest efficacy and frequent adverse effects, underscoring the urgent need for new therapeutic approaches. Celastrol, a triterpene compound derived from traditional Chinese medicine, exhibits anti-inflammatory activity and broad anti-tumor effects, including sensitization of cancer cells to chemo- and radiotherapy. In this study, we investigated for the first time the anti-cancer potential of celastrol in the ACC H295R cell line. Using different in vitro biomolecular technologies and biochemical/biophysical experiments, we evaluated celastrol's effect on ACC cells. Celastrol induced apoptosis in ACC cells and demonstrated efficacy not only in 2D monolayer cultures but also in 3D spheroid models. Importantly, it inhibited spheroid growth and disrupted pre-formed spheroids, highlighting its activity in tumor-like structures. Mechanistic analyses suggested that celastrol triggers apoptosis through induction of endoplasmic reticulum (ER) stress and oxidative stress. These findings parallel our previous observations with mitotane, which also activates the ER stress pathway via the ATF4-ATF3 axis. This partial convergence points to ER stress induction as a potential therapeutic target in ACC. identifying agents capable of complementing or replacing standard therapy remains a central challenge in ACC research. Our findings suggest that celastrol is a potent bioactive compound with activity against both monolayer and 3D ACC models, offering potential translational relevance. By elucidating ER stress as a shared mechanism between celastrol and mitotane, our work supports further exploration of this pathway as a strategy to potentially improve therapeutic outcomes in ACC patients.

9 August 2026 in New Biotechnology
Verified
Journal Article
Open access
ASAurora Schiavon
Aurora Schiavon
CECarlotta Evaristo
Carlotta Evaristo
LSLaura Saba
Laura Saba
Jessica PetitiJessica Petiti
Jessica Petiti
CLChiara Longo
Chiara Longo
MIMarco Lo Iacono
Marco Lo Iacono
Programmed cell death (PCD) is a fundamental biological process required for tissue homeostasis and the removal of damaged or infected cells. Apoptosis, one of the most studied PCD modalities, is routinely assessed using the Annexin V/propidium iodide (PI) assay. However, the conventional Annexin V/PI protocol frequently produces false-positive necrotic signals due to membrane damage caused during cell harvesting and handling. This artifact compromises the metrological accuracy of necrosis quantification, limiting assay standardization in cancer research and potentially leading to the premature exclusion of promising anticancer compounds during in vitro screening. To address this issue, we developed a modified Annexin V/PI protocol designed to improve the reliability of necrosis detection. In the optimized approach, PI is added directly to the culture medium prior to cell harvesting, allowing uptake exclusively in cells with truly compromised membrane integrity. This strategy effectively reduces handling-induced artifacts and provides a more accurate evaluation of the membrane-compromised population. Precise discrimination between apoptotic and necrotic cells is essential for standardized cellular assays and for the accurate interpretation of drug-induced cytotoxic effects. Our revised protocol enhances accuracy, reproducibility, and robustness of apoptosis assessment, particularly in fragile cell systems, while remaining fully compatible with commercially available Annexin V/PI detection kits.